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Abstract.  Measurements of nucleocytoplasmic trans- 
port of fluorescent-labeled macromolecules were per- 
formed in both an EGF-nonresponsive mutant fibroblast 
line (3T3-NR6) and in the same cell line reconstituted 
with active EGF receptors derived from rat hepatic 
membrane fraction. Immunolocalization studies of ex- 
ogenously incorporated EGF receptors in reconstituted 
3T3-NR6 fibroblasts demonstrated predominantly intra- 
cellular localization. The EGF receptor constructs also 
showed EGF-stimulated incorporation of [3H]thymi- 
dine, providing biochemical evidence for functional in- 
tegration of the exogenously supplied EGF receptors 
into the reconstituted fibroblasts. Additional support 
for the functional incorporation of receptor may be in- 
ferred from the enhanced cellular accumulation of 
~2SI-EGF in cells treated with chloroquine and leupep- 
tin.  ~25I-EGF binding and transnuclear macromolecular 
transport measurements in mutant and reconstituted 
cells, in conjunction with such measurements on 
nuclei isolated from these cells, provide data consis- 
tent with a  growth factor/nuclear signaling mechanism 
dependent on the nuclear acquisition of EGF binding 
activity from the plasma membrane. 
p 
OLYPEPTIDE growth factors and hormones serve as 
regulatory molecules for cell differentiation and also 
as initiators of coordinated cellular responses to ex- 
tracellular metabolic variation (15). Cell type-specific growth 
factor receptors in the plasma membrane of  cells serve as the 
primary targets and ultimate discriminators for the large 
number of growth factors in the cellular environment (42, 
43, 48). A question central to the mechanism of polypeptide 
growth factor signaling has been whether ligand-activated 
plasma membrane receptors (by themselves or in functional 
aggregates with other effector macromolecules [20, 22, 41]) 
produce a nuclear response uniquely as a result of either di- 
rect translocation to the nucleus (receptor translocation acti- 
vation mechanism) (12,  17, 25,  27,  32,  33, 46,  47)  or in- 
directly through the intracellular production of secondary 
messengers (14, 30) initiated by growth factor-mediated re- 
ceptor kinase stimulation at the plasma membrane or a com- 
bination of multiple excitatory paths. An integrating control 
point for nuclear activation has been suggested to be the 
transnuclear transport channel defined by the nuclear pore 
complex (1, 34). It appears likely that growth factor-induced 
cellular changes would include modifications of bidirectional 
macromolecular transport through the nuclear pore complex. 
Previous work has demonstrated significant dose-dependent 
changes in nuclear macromolecular transport after addition of 
either EGF or insulin to 3T3 fibroblasts  (16). That this type 
of activation could be related to nuclear receptor occupancy 
was suggested by demonstrations of enhanced EGF or insulin- 
induced macromolecular and RNA nuclear transport in iso- 
lated rat liver nuclei (2, 32, 36). Although these experiments 
and others are consistent with an occupancy-dependent effect 
of growth factor receptors  on nuclear function, the question 
of whether the observed effects are a result of indigenous nu- 
clear growth factor receptors or the migration of ligand-bound 
plasma membrane receptors  to sites in the nucleus has been 
unclear (25, 46). To pursue this question of receptor localiza- 
tion and transport, we have used a technique developed  by 
Bishayee et al. (3) in which EGF receptors  are transferred in 
a biologically active state from donor hepatic membranes to 
receptor-deficient fibroblasts (3T3-NR6) (26), resulting in cells 
that are physically reconstituted with receptors. Such EGF 
receptor constructs were demonstrated to be responsive to 
EGF as measured by stimulation of DNA replication and cell 
division (3). Although molecular biological approaches have 
recently superseded many physical reconstitution protocols 
for receptor structure/function analyses (9, 11, 19), the moti- 
vation for choosing physical reconstitution approaches was 
based on the need to create a specific topologically defined 
placement of  the receptor at the plasma membrane. Introduc- 
tion of an EGF receptor gene into a receptor mutant results 
in expression and cellular localization at a number of intra- 
cellular sites (11), obscuring attempts to discriminate between 
indigenous nuclear localization of the EGF receptor or nu- 
clear localization as a  result of EGF-induced migration of 
these receptors from the plasma membrane to the nucleus. 
We now show, using the method of receptor reconstitution 
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lar transport by EGF is concomitant with plasma membrane- 
derived EGF binding activity appearing at the nucleus.  In 
addition, nuclei isolated from EGF-nonresponsive cells (3T3- 
NR6)  after coincubation  with  rat liver  EGF receptor-en- 
riched  plasma  membrane fraction  become  responsive  to 
EGF-induced enhancement of dextran transport. 
Materials and Methods 
Reagents 
Fluorescein-laheled dextrans (FITC-dextrans) (20,000  and 70,000  mol wt, 
designated 20K and 70K, respectively), chioroquine, and leupeptin were 
obtained from Sigma Chemical Co. (St. Louis, MO). Tritiated thymidine 
(10 Ci/mmol) was obtained from ICN Radiochemicals (Irviue, CA). EGF 
was from Gibco Laboratories (Grand Island, NY),  while 125I-EGF (152 
/tCi//~g)  was obtained from New England Nuclear (Boston,  MA). 31"3-1 
(3T3 Swiss albino) cells were obtained from American 2~ype Culture Col- 
lection (Rockville, MD), while the 3T3-NR6 EGF nonresponsive cell line 
isolated from murine Swiss albino 3T3 cells was a kind gift of Dr. H. R. 
Herschman,  Laboratory  of  Biomedical  and  Environmental  Sciences, 
University of California at Los Angeles, School of Medicine (Los Angeles, 
CA). Monoclonal anti-monse EGF receptor antibody, clone 29.1 (mouse 
ascites fluid), and FITC-conjugated goat anti-mouse IgG were from Sigma 
Chemical Co. 
Cell Growth, Fluorescent Dextran Incorporation, and 
Receptor Insertion 
Cells were normally grown and maintained at 37°C in DME containing 10% 
FCS  in a  10%  CO2  atmosphere, unless otherwise indicated. Cell syn- 
chronization and scrape-loading of fluorescein-derivatized  dextrans (Frl'c- 
dextrans; 20,000  mol wt) was performed as previously described (16, 33). 
Scrape-loading is a technique used to incorporate FITC-dextrans into the 
cell cytoplasm to serve as neutral transport probes for the fluorescence pho- 
tobleaching method of measuring transnuclear transport  (16, 33).  Cell 
growth and viability studies suggest that replated, scrape-loaded cells he- 
have normally (16, 33, 40).  EGF receptor-deficient 3T3-NR6 cells were 
replated on 35-ram tissue culture dishes immediately after scrape-loading 
and incubated in DME containing 2% calf serum at 370C for 2.5 h. After 
reattachment and spreading, the cells were ready for EGF receptor inser- 
tion. The hepatic EGF receptor fraction used for insertion was isolated from 
fresh rat livers that were suspended in cold 1 mM NaI-ICO3 buffer.  Plasma 
membrane fraction was isolated as described by Emmelot et al. (8) with 
modifications. After sucrose gradient equilibrium centrifw,  ation, the mate- 
rial at the interface and immediately below it was collected, pooled, and 
diluted approximately fivefold with 1 mM NaI-ICO3 buffer.  After centrifu- 
gation at 9,500 rpm for 20 min in a rotor (JA-I; Beckman Instruments, Inc., 
Follerton, CA), the plasma membrane pellets were resuspended in buffer 
at an approximate protein concentration of 20 mg/mi and either stored at 
-20°C or processed for EGF receptor insertion. The specific EGF binding 
activity of this  fraction was determined to be 0.5-1  lnnOl of n5I-EGF 
buund/mg of total protein under standard incubation conditions (60-min in- 
cubation  with  10  nM  12SI-EGF at  200C).  Similar approaches to  EGF 
receptor isolation, showing approximately the same t25I-EGF  binding to 
isolated membranes as described here, have demonstrated that the receptor 
is fully functional as measured by binding kinetics and EGF-dependent au- 
tophosphorylation (18). The EGF receptor insertion e~pariments were per- 
formed as described by Bishayee et al. (3) for mouse hepatic EGF receptor 
fraction. For nuclear transport measurements, monolayers of 20K FITC- 
dextran-loaded 3T3-NR6 cells in 35-ram dishes were grown in DME plus 
2 % calf serum for 2.5 h, and then liver plasma membrane fraction contain- 
ing 125I-EGF binding activity was added at 0.5 mg membrane protein/nil 
and incubated for 6 h at 26°C. At the end of incubation, dishes were washed 
five times with I-IBSS and Hepes followed by five sequential washes with 
DME to remove unbound membranes. At maximal insertion (500/~g mem- 
brane protein/10  s cells), nol06 EGF binding sites could he incorporated per 
3T3-NR6 cell. The cells were then incubated in DME with 2% calf serum 
in the absence or presence of various combinatiom of leupeptin, chloro- 
quine, and EGF. Subsequently, either these cells were assayed for cellular 
and nuclear EGF accumulation or nuclear transport measurements were 
performed using the FRAP technique (16, 33). For cell cycle experiments, 
ceils were induced into the quiescent state (Go) by washing three times with 
DME and then maintained in DME for 30-38 min. These cells were then 
scrape-loaded with 20K FITC-dextran and then replated on fibrouectin- 
coated dishes in DME. After 2-3 h, cells were sufficiently spread for trans- 
port measurements. 
~I-EGF Binding Studies to Whole Cells and 
Isolated Nuclei 
Cellular and nuclear accumulation of 12SI-EGF (152 ~tCi//~g; New England 
Nuclear) in 31"3-1 in the absence or presence of chloroquine or leupeptin 
were performed as described by Savion et al. (31) and Pruss and Herschman 
(26) with some modifications. Confluent 31"3-1 cell cultures ("~5  x  105 
cells/35-mm dish) had their media replaced by fresh DME plus 10% calf 
serum. Cultures containing lysosomotropic reagents were preincubated in 
the presence of chioroquine (12/tM) for 2 h or in the presence of leupeptin 
(100 ~tg/mi) for 16 h before the addition of 125I-EGF (31). After incubation 
at 37°C with 12SI-EGF for 20 h, the cultures were washed eight times with 
ice-cold PBS-BSA (1 mg/ml BSA), and then the dishes were incubated on 
ice for 20-30 rain in lysis buffer (15 mM Tris-HCl [pH 7.4], 2 mM EDTA, 
0.5 mM EGTA, 60 mM KCI, 15 mM NaC1, 0.15 mM spermiue, 0.5 mM 
spermidine, 15 mM/~-mercaptoethanol,  0.5 % NP-40, and I mM PMSF [26, 
31]). The cell lysate fraction was collected, and the hound t25I-EGF was 
quantitated in a  liquid scintillation counter (LS  100C;  Beckman Instru- 
ments, Inc.). Nouspecific binding was determined  in the presence of a 20- 
fold excess of unlabeled EGE Such binding ranged from 5 to 12% of the 
total 125I-EGF binding and was subtracted from all values. All assays were 
performed in duplicate, and the values reported represent the mean. Nuclei 
for binding studies were prepared in the following manner (31). After col- 
lecting the whole cell iysate described above, a  monolayer of nuclei re- 
mained anchored to the cell culture dish. These nuclei were washed 8-10 
times with PBS-BSA. I ml of donble-distilled water was then added to each 
35-mm dish, and the nuclei were removed by gentle pipetting. The resulting 
nuclei were then layered on an 0.5-ml sucrose cushion (0.5 M) and cen- 
trifuged for 15 min at 10,000 g at 4°C. The supernatant was discarded, and 
the radioactivity in the nuclear pellets was counted as described above for 
the cell lysate. Electron microscopic analysis of these fractions by Savion 
et al. (31) showed the absence of lysosomal vesicles, whether or not cells 
were pretreated with chloroquine, while an acid phosphatase assay demon- 
strated gl% of the total acid phosphatase activity in the isolated nuclear 
fraction. In the case of 3T3-NR6 cells, monolayers of NR6 cells in 35-ram 
dishes were treated with the membrane fraction for EGF receptor insertion 
(described above and in reference 3) and then incubated with 12SI-EGF as 
described for 3T3-1 cells. 
rH]Thymidine  Uptake Measurements in 
Whole Cells 
Monolayers of cells were grown in 12-well clusters and incubated at 26°C 
for ~,6 h with 500/~g/ml of rat liver plasma membrane fraction in DME 
containing 2% calf serum. The cells were then washed free of unbound 
membrane and incubated at 37°C in DME and 2% calf serum for "~24 h. 
40 ng/mi of EGF was added to medium and incubated for 12 h. At the end 
of incubation, 15 FtCi/mi of [3H]thymidiue was added to cells followed by 
an additional  12  h  of incubation.  Incorporated [3H]thymidine was then 
measured by TCA precipitation. The data represents measurements with the 
standard deviation indicated by bars. 
Fluorescence Measurements: FRAP and 
Immunolocalization 
FRAP was performed as previously described for isolated nuclei and whole 
cells (16, 33) with the following modification for isolated nnclear measure- 
ments. 3T3 nuclei were isolated as described above for s2SI-EGF binding 
studies. Monolayers of nuclei remaining attached to the 35-mm tissue cul- 
ture plate were equilibrated in 70K FITC-dextran solution for nuclear trans- 
port measurements. Repeated bleaching on the same sample was used to 
serve as an assay for photodam~e. Fluorescence immunofocalization of 
EGF receptor on whole 3T3-NR6 and 3T3-1 pment cells was performed in 
the following manner. Cells were grown at 37°C in DME containing 10% 
calf  serum in a  10% C02 atmosphere. They were then washed several 
times  with  PBS  and  treated  for  "ol  min  with  methanol/acetone (3:7 
[vol/vol]) at room temperature for fixation. Fixed cells were then air dried 
and rinsed in PBS. Dried cells were then incubated with the monoclonal 
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for 2 h at room temperature.  The cells were then washed three times and 
incubated with FITC-conjugated goat anti-mouse IgG (1:50).  After a thor- 
ough washing with PBS, fluorescence stain was observed using an epifluo- 
rescence photomicroscope (E. Leitz, Inc., Wetzlar,  FRG). Mouse nonim- 
mune serum was used as a control. 
Results 
t25I-EGF Binding to Whole Cells and Nuclei 
Experiments to explore the mechanism and cellular pathway 
of EGF-induced activation of transnuclear transport were 
initiated by determining EGF binding activity on the cellular 
and nuclear level. The data presented in Fig. 1 demonstrate 
steady-state ~25I-EGF accumulation for whole 3T3-1 cells 
(Fig. 1, A and C) and for nuclei isolated from them (Fig. 1, 
B and D). Nuclear accumulation under these conditions was 
clearly saturable. It is particularly noteworthy that addition 
of chloroquine (12 ~M; Sigma Chemical Co.) (Fig. 1, A and 
B) or leupeptin (100 pg/ml; Sigma Chemical Co.) (Fig.  1, 
C and D), agents affecting receptor recycling and degrada- 
tion at different  points in the endosomal pathway (6, 7, 13, 23), 
resulted in significantly  enhanced whole cell (cell lysate) and 
nuclear '~-EGF accumulation. These results parallel obser- 
vations by Savion et al. (31), demonstrating that inhibitors of 
lysosomal hydrolytic activity or endosomal-lysosomal fusion 
enhance cellular and nuclear accumulation of EGF in cul- 
tured bovine corneal endothelial and granulosa cells. A chlo- 
roquine-induced enhancement of  nuclear localization for EGF 
receptor was also reported by Murthy et al. (24) using anti- 
EGF receptor and anti-EGF kinase domain antibodies as 
probes. Further analysis of EGF binding is presented in Fig. 
2, demonstrating that chloroquine and leupeptin can enhance 
nuclear accumulation from a value of '~ 2 % of total bound 
'25I-EGF to ~8-10% (Fig. 2, A and B). Although somewhat 
difficult to assess due to the low level of bound radioactivity, 
half-maximal nuclear accumulation appeared to occur Imtween 
2 and 5 h. These experiments demonstrate not only that nu- 
clear EGF accumulation occurred but that this activity could 
be considerably enhanced in the presence of inhibitors of en- 
dosomal-lysosomal fusion (chloroquine) (6,  7,  13,  23)  or 
cathepsin B activity (leupeptin) (45). 
The half-time for nuclear accumulation of *25I-EGF in the 
presence of leupeptin (Fig. 2, B and D) is similar to that ob- 
served in the presence of chloroquine. No specific '25I-EGF 
binding was observed to whole cells or nuclei isolated from 
them after incubation with  EGF-nonresponsive 3T3-NR6 
cells. These experiments help to eliminate the possibility of 
nonspecific trapping, other non-EGF receptor proteins that 
may associate with EGF,  or functional internalization by 
fluid phase endocytosis. The observation that half-maximal 
nuclear accumulation of '2SI-EGF occurs after *2-5 h may 
explain recently reported negative results by Carpentier et al. 
(4), who do not observe nuclear localization of EGF receptor 
after only 1 h of incubation. It is important to point out that 
under similar experimental conditions for measuring EGF 
binding to fibroblasts, Wiley et al. (45) showed that 92 % of 
EGF associated with responsive human fibroblasts is located 
in an intracellular compartment. They further showed that 
*60% of the internalized '25I-EGF remained in a form that 
could still bind to EGF receptors. 
Reconstitution of  EGF Receptor into 
EGF-nonresponsive 3T3-NR6 Cells 
Bishayee et al. (3) demonstrated that EGF receptors could 
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Figure 1.  125I-EGF binding to whole cells 
and nuclei isolated from 31"3-1 fibroblasts. 
Cellular and nuclear accumulation studies 
of nSI-EGF in 3'1"34 cells in the absence 
and presence of chloroquine or leupeptin 
were performed as described in Materials 
and  Methods. Binding of  nZI-EGF to 
whole 3T3-1 cells  (A) and their  isolated 
nuclei (B) in the absence (*) and presence 
(A)  of  chloroquine  (12  /~M). nSI-EGF 
binding to whole 3T3-1 cells (C) and their 
isolated nuclei (D) in the presence (*) of 
leupeptin (100 ttg/ml). 
Jiang and Schindler  Nuclear Accumulation of EGF Affects Nuclear Transport  561 500 
400 
S 
e,  500 
t- 
rn  2O0 
U_ 
Ixl 
~'~  I00 
if) 
~  64o 
480 
E 
m  320 
Lt_ 
L9 
Ld 
160 
to 
=~_  / 
./  ..d  " 
/ 
/  ~o~  ,~  ~  ~'o 
Chloroquine  ~t~M~ 
I0  20  30 
Chloroquine  ~M] 
C  o 
0  I0  20 
Time (h) 
5  I0  15  20 
Time  (h) 
=11=11  2 
EL  I /  '~"  -  50  150  2~0  _ 
o  5o  ,oo  ,5o  2oo  zso 
Leupeplin [/zg/ml] 
560 
if} 
420 
b  i,i 
0 
/  ~,o~ 
V  I  I  I 
Time (h) 
I 
I0  20  30 
Time  (h) 
Figure 2. Effect of chloroquine and leupep- 
tin on cellular and nuclear accumulation of 
125I-EGF  in  3"1"3-1 fibroblasts,  m25I-EGF 
binding experiments were performed as de- 
scribed  in  Materials  and  Methods.  1251- 
EGF binding in whole 3T3-1 cells (&) and 
their nuclei (•) as a function of concentra- 
tion  of chloroqine  (.4) or leupeptin  (B). 
Time course of n5I-EGF binding to whole 
3T3-1 cells (&) and their nuclei (•) in the 
presence of 12 itM chloroqulne (C) or 100 
~tg/ml leupeptin (D).  125I-EGF  concentra- 
tion  was  20  ng/ml.  Insert  in each  panel 
shows the increase in nuclear accumulation 
of 125I-EGF as a percentage of the total cell 
accumulation (whole cell  lysate plus  nu- 
clear) as a function of chloroquine (,4) or 
leupeptin  (B) concentration and  time  (C 
and D). 
be transferred in a biologically active state from donor he- 
patic membranes to receptor-deficient fibroblast cells (3T3- 
NR6).  Enrichment for EGF receptor insertion when com- 
pared with bulk membrane protein from the donor hepatic 
membranes into the recipient cells was ~19-fold at 26°C (3). 
A  Scatehard analysis of the donor EGF receptor demon- 
strated an apparent K~ of '~ 2.4 nM (3). Labeling the donor 
membrane with a photoreactive derivative of ~25I-EGF re- 
suited in the specific radiolabeling of a  170,000-D  polyp•p- 
tide which was identical to the EGF receptor (3). The EGF 
receptor constructs prepared from the above-mentioned do- 
nor hepatic  membranes  acquired  EGF  responsiveness as 
measured by stimulation of DNA replication and cell divi- 
sion (3). Fig. 3 demonstrates the cellular localization of ex- 
ogenously incorporated rat liver EGF receptor reconstituted 
as described (Materials and Methods) (Fig. 3, A and B). This 
is to be compared with the receptor distribution in parental 
3T3-1 cells (Fig. 4, A and B). The higher levels of fluores- 
cence observed for the receptor construct probably reflects 
the greater number of cellular receptors (approximately two- 
fold; Table I). The fluorescence micrographs show a similar 
cellular distribution of EGF receptors when compared with 
results from other laboratories (11, 24). EGF-nonresponsive 
3T3-NR6 demonstrates no cellular EGF receptor labeling 
(Fig. 3, C and D), consistent with its nonexpression in this 
mutant eeU line (35) and lack of t~I-EGF binding (Table I). 
Fig. 4, C and D, is the nonimmune control for the parental 
3T3-1 cell line.  The immunolocalization data provide evi- 
dence for physical integration of the rat liver EGF receptor 
and  subsequent internalization into the  3T3-NR6 mutant. 
The results presented in Fig. 5 support the original observa- 
tions of Bishayee et al. (3) that the exogenously incorporated 
receptor enables the 3T3-NR6 mutant to respond to EGF as 
reflected by pl-I]thymidine uptake experiments (see Materi- 
als and Methods). It can be observed in Fig. 5 A, column 
2, that the 3'I"3-1 parent cell line responds to EGF by enhanced 
uptake of [3H]thymidine. Treatment of 3T3-1 cells with rat 
liver EGF receptor fraction in the manner used to reconsti- 
tute the 3T3-NR6 mutant did not significantly enhance pH]- 
thymidine uptake (Fig. 5 A, column 4). As previously demon- 
strated, the 3T3-NR6 mutant did not respond to EGF (Fig. 5 
B, column 2). After incorporation of exogenously added rat 
liver EGF receptor fraction, the reconsituted 3T3-NR6 ceils 
showed EGF-mediated enhancement of [3H]thymidine uptake 
(Fig. 5 B, column 4) to the extent observed for the parent 
3T3-1 cell line (Fig. 5 A, column 2). The data presented in 
Fig. 3 and Table I support the idea that exogenously incor- 
porated rat  liver EGF  receptor fraction can  successfully 
integrate into the plasma membrane and then undergo inter- 
nalization with apparent redistribution to intracellular com- 
partments. The sensitivity to chloroquine and leupeptin (Ta- 
ble I) provides further evidence that the incorporation and 
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3T3-NR6 EGF receptor constructs as deter- 
mined  by  indirect  immunofluoreseence. 
Cells  grown  in  monolayer  were  fixed, 
processed,  and  stained  for  indirect  im- 
munofluorescent  analysis  as  described  in 
Materials  and  Methods.  Phase  (A)  and 
fluorescent (B) views of reconstituted cells. 
Phase (C) and fluorescent (D) views of  non- 
reconstituted  mutant NR6 cells  stained as 
above. 
intracellular processing of the exogenously incorporated re- 
ceptor mimics that of other cell lines under similar condi- 
tions of endosomal and lysosomal alkalinization (23, 24, 45). 
Comparative Analysis of  EGF-mediated 
Enhancement of Transnuclear Transport in 
Whole Cells and Nuclei  from 313-1, 3T3-NR(~ 
3T3-NR6 EGF Receptor Constructs 
Nuclear Transport Measured in Whole Cells. To examine 
the  correlation  between  the  ~2SI-EGF binding  capacity of 
whole cells,  nuclei  isolated from them, and nuclear trans- 
port, we initiated a  series of transnuclear transport experi- 
ments to pursue a direct comparison between nuclear accum- 
ulation of EGF binding activity and transnuclear transport 
for 3T3-1, 3T3-NR6, and 3T3-NR6 EGF receptor constructs 
and nuclei isolated from these cells. A compilation of these 
results is presented in Tables I and 1I. In view of our binding 
assay in  which  unbound  or processed  ~25I-EGF should  be 
solubilized (38, 45), it is considered likely that EGF binding 
activity reflects the presence of either functional EGF recep- 
tors or EGF receptor in complex with other activated macro- 
molecules (20, 22, 41).  An initial view of the data in Table 
I suggests that nuclear occupancy of '~420 receptors per nu- 
cleus  or 2.8%  of the  total cellular bound  ~25I-EGF in  the 
parental 3T3-1 line is sufficient to maximally enhance nucleo- 
cytoplasmic transport in whole cells (approximately three- 
fold).  Addition  of chloroquine  (15  #M)  increases  nuclear 
EGF accumulation to a much greater extent (eightfold) than 
the enhancement observed for whole cell binding. A similar 
enhancement in binding was observed in the presence of leu- 
peptin (data not shown).  No greater increase, however, for 
transnuclear transport in whole cells is observed after chlo- 
roquine treatment.  This is consistent with the observation 
that transport rates in the absence of chloroquine appear to 
be the maximal rates obtainable in both whole cells under 
conditions of EGF stimulation or transformation (16).  3T3- 
NR6 EGF receptor constructs in the presence of EGF dem- 
onstrate nuclear EGF binding activity and a significantly en- 
hanced rate for nuclear transport (approximately twofold) in 
whole cells (Table I).  The 3T3-NR6 mutant without EGF 
receptor displays neither ~25I-EGF  binding activity for whole 
cells nor enhancement of nuclear transport in whole cells as 
a result of EGF addition (Table I). After exposure to chloro- 
quine, the 3T3-NR6 EGF receptor constructs show enhanced 
nuclear accumulation in a manner similar to the parent 3T3-1 
(Table I). 
Nuclear Transport Measured in Isolated Nuclei. To ex- 
amine whether the whole cell measurements of nucleocyto- 
plasmic transport in 3"1"3-1 and 3T3-NR6 EGF receptor con- 
structs are a reflection of modified transport activity in nuclei 
isolated from them, dextran transport experiments were per- 
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3"1"34  cells  as determined by  indirect  im- 
munottuorescence.  Fixing  and  staining 
were performed as described in Fig.  3  and 
Materials  and  Methods.  Phase  (A)  and 
fluorescent (B) views of 3T3-1 cells. Phase 
(C) and fluorescent (D) views of 3T3-1 cells 
probed  with nonimmune serum. 
Table L  Correlation of Transnuclear Dextran Transport Rate in Whole Cells with Cellular and Nuclear EGF Accumulation 
Cell line/treatment  Cellular accumulation of EGF*  Nuclear bound EGF~  Dextran transport rate§  Change from control 
EGF molecules per celltl  EGF molecules  per nucleusll  x  lO~s-ql  % 
3T3-1  (parent)  (control)  -  -  6.4  -t-  1.6  (8)  I  - 
3T3-1  +  EGF  15,000  +  1,600  420  -k  160  19.7  +  3.0 (19)  +208 
3T3-1  +  chloroquine  47,000  +  5,000  3,400  +  1,300  18.9  +  2.7 (13)  +195 
(15  /~M)  +  EGF 
3T3-NR6  -  -  7.1  +  1.0 (7)  +  11 
3T3-NR6  +  EGF  ND  ND  7.4  -t-  1.5  (12)  +  16 
3T3-NR6 EGF  receptor  -  -  6.1  :t:  1.8 (7)  -  5 
construct 
3T3-NR6 EGF  receptor  24,000  +  2,600  350  +  200  12.1  +  3.2 (9)  +  89 
construct  +  EGF 
3T3-NR6 EGF  receptor  50,000  +  7,300  7,600  +  500  13.6  +  3.5  (11)  +113 
construct  +  chloroquine 
(30/tM)  +  EGF 
* Cells were incubated with *2SI-EGF  for 20 h at a concentration of 20 ng/ml and then lysed in lysis buffer (Materials and Methods), and the *2SI-EGF activity 
of lysate was counted as described in Materials and Methods. 
~: Cells were incubated  with ~25I-EGF for 20 h at a concentration of 20 ng/ml, the nuclei were subsequently isolated, and *251-EGF  activity was counted (Materials 
and Methods). 
§ Transport rate constant of 20K FITC-dextrans (Sigma Chemical Co.) in whole living 3T3 cells. In the case of EGF (LR-EGF; Collaborative Research, Inc., 
Bedford, MA) stimulation, the transport measurements were performed after adding EGF (50 ng/ml) to 20K FITC-dextran-loaded culture cells and incubating 
at 37°C for 3-6 h. FRAP experiments were performed as described (16, 33). 
I[ Mean  ±  SD. 
I Number of experiments (in parentheses). 
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Figure 5. EGF-induced  stimulation  of DNA synthesis  in 3T3-NR6 
EGF receptor constructs andthe parent 3T3-1 cell line. A represents 
[3H]thymidine  incorporation  for the 31"3-1 parent cells,  while B 
represents the [3H]thymidine uptake in the 3T3-NR6 EGF receptor 
constructs.  The measurement  conditions  involved are  (column 
1-4, respectively)  no rat hepatocyte receptor fraction pretreatment 
formed on isolated nuclei (isolated from variously treated 
cells as described in Materials and Methods). A comparison 
of nuclear transport results for 3T3-1  nuclei isolated from 
cells grown for 20 h in media containing 2 % calf serum but 
no EGF (unprimed) with nuclei isolated from cells grown in 
media containing EGF (20 ng/ml; primed) demonstrates that 
only in the nuclei isolated from primed cells can EGF (50 
ng/ml added to the transport assay) enhance macromolecular 
transport (+136%). Measurements of transport with nuclei 
isolated from primed cells containing no EGF in the trans- 
port assay demonstrated no significant enhancement (Table 
H). The enhancement observed for nuclei isolated from primed 
cells in the presence of EGF was found to be larger when 
nuclei were isolated from primed cells that had also been 
treated with chloroquine (15 #M) (as described in Materials 
and Methods). These results would support the idea that an 
induction in the cell of EGF binding activity and a subse- 
quent nuclear accumulation of EGF binding capacity is re- 
quired to successfully modulate nuclear transport (Tables I 
and H). Nuclei isolated from the EGF-nonresponsive mutant 
(3T3-NR6) demonstrated no enhanced nuclear transport af- 
ter isolation from primed or unprimed cells in the presence 
or absence of EGF (50 ng/ml) in the transport assay.  The 
nor EGF addition, no rat hepatocyte receptor fraction pretreatment 
and 40 ng/ml EGF, rat hepatocyte receptor fraction reconstitution 
and no EGF, and rat hepatocyte receptor fraction reconstimtion and 
40 ng/ml EGE Error bars represent the standard deviation for three 
measurements. Incubation and reconstitution procedures are as de- 
scribed in Materials and Methods. 
Table II. Transnuclear Dextran Transport Rate in Isolated Fibroblast Nuclei 
Nuclei and cell treatment  Dextran transport rate*  Change from control 
Nuclei from parent cell line 
3T3-1  (parent) (control) grown without EGF and containing no EGF in the nuclear 
transport assay 
3T3-1  grown without EGF but containing EGF (50 ng/ml) in the nuclear 
transport assay 
3T3-1  grown in presence of EGF (20 ng/ml) but containing no EGF in the nuclear 
transport assay 
3T3-1  grown in presence of EGF (20 ng/ml) and containing EGF (50 ng/ml) in the 
nuclear transport assay 
3T3-1  pretreated with chloroquine (15 #M) (Materials and Methods), grown in the 
presence of EGF (20 ng/ml), and containing EGF (50 ng/ml) in the nuclear 
transport assay 
Nuclei from EGF-nonresponsive cell line 
3T3-NR6 grown without EGF and containing no EGF in the nuclear transport assay 
3T3-NR6 grown without EGF but containing EGF (50 ng/ml) in the nuclear 
transport assay 
3T3-NR6 EGF receptor construct 
3T3-NR6 EGF receptor construct with EGF (50 ng/ml) in the transport assay 
3T3-NR6 EGF receptor construct pretreated with chloroquine (15 ~M) and containing 
EGF (50 ng/ml) in the nuclear transport assay 
3T3-NR6 nuclei coincubated with EGF receptor fraction containing no EGF in the 
nuclear transport assay 
3T3-NR6 nuclei coincubated with EGF receptor fraction and then stimulated with 
EGF (50 ng/ml) in the transport assay 
x  lObs-It  % 
3.3  5:1.0  (5)~ 
3.8  5:1.4  (9)  +  15 
3.8  5:0.5  (3)  +  15 
7.8  5:1.2  (8)  +136 
9.6  5:1.5  (6)  +191 
2.4  +  0.8  (6) 
2.3  +  0.6  (8)  -  4 
3.7  +  1.1  (7)  +  54 
6.5  +  0.8  (9)  +171 
8.3  5:1.3  (9)  +246 
1.9  5:1.0  (3)  -  20 
7.5  5:1.1  (12)  +213 
* Transport measurements for 70K dextrans (isolated nuclear measurements) were performed after adding 50 ng/ml EGF 
at 370C for 2.5 h. 
$ Mean  5:  SD. 
§ Number of experiments (in parentheses). 
to the isolated nuclei and incubation 
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tained for 3T3-NR6 cells support the notion that the absence 
of an EGF effect on nuclear transport may most simply be 
explained by the absence of nuclear-localized EGF binding 
capacity. Under these conditions, no EGF-mediated enhance- 
ment of nuclear transport is observed when monitored in 
whole cells or nuclei isolated from them (Table I and II). If, 
however, nuclei are isolated from 3T3-NR6 cells after EGF 
receptor fraction reconstitution into the plasma membrane 
and stimulated with EGF, nuclear transport is increased (Ta- 
ble 1I) to appro  "xn'aately  the same extent as reported for nuclei 
isolated from the primed parent (3T3-1) cells (Table II). This 
is directly related to an EGF-mediated process in the recon- 
stituted cells since the nuclei from 3T3-NR6 receptor con- 
structs not incubated with EGF did not demonstrate enhanced 
transport. The 3T3-NR6 receptor construct also responded 
to chloroquine treatment in the same manner as the parent 
3T3-1 cell line, in that nuclear transport in nuclei isolated 
from the chloroquine-treated cells was somewhat enhanced 
over nonchloroquine treatment. To examine whether the rat 
liver EGF receptor fraction by itself was sufficient to enhance 
transport, isolated 3T3-NRfi nuclei were directly coincubated 
with EGF receptor fraction. Incubation was performed as de- 
scribed for whole cell reconstitution, using isolated NR-6 nu- 
clei instead of cells (Materials and Methods).  Under these 
conditions, the nuclei again demonstrated enhanced transport 
in the presence, but not absence, of EGF (50 ng/ml in the 
transport assay) to the extent observed for nuclei isolated from 
primed 3T3-1 cells and 3T3-NR6 EGF receptor constructs. 
Correlation between Nuclear Accumulation of  EGF 
and the Transnuclear Dextran Transport Rate in 
Whole Cells 
In an attempt to establish a minimal level for transnuclear 
transport activity, we measured EGF-mediated enhancement 
of nucleocytoplasmic transport in whole 3T3-1 fibroblasts not 
exposed to EGF in the growth medium (2 % calf serum) and 
maintained at Go in the cell cycle (see Materials and Meth- 
ods). The result for transnuclear dextran transport measure- 
ments in whole 3T3-1 cells at Go is 3.2 +  0.7 ×  10  -3 s-' (five 
measurements on different cells +  SD). To examine the cor- 
relation between whole cell nuclear transport and EGF re- 
ceptor nuclear occupancy, we have plotted this value (Fig. 6, 
point A) with the other experimentally derived values (Fig. 
6, points B-D, are from Table I). As pointed out in the legend 
to Table I, ~25I  binding measurements were performed in the 
presence of 20 ng/ml ~25I-EGF, while dextran transport was 
performed at 50 ng/ml EGE Considering that Fig. 1 A dem- 
onstrates saturation binding for 3"1"3-1 nuclei at 10 ng/ml, we 
believe this comparison is valid. A linear relationship is ob- 
served between the extent of nuclear ~25I-EGF accumulation 
and enhanced transport. 
Discussion 
Receptor Translocation Activation Mechanism for 
Direct Modulation of Nuclear Function 
The data presented provide evidence that modulation of a 
significant nuclear function, nucleocytoplasmic communica- 
tion in fibroblasts stimulated with EGF, is concomitant with 
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Figure 6. Transnuclear dextran transport rate as a function of EGF 
receptor nuclear occupancy. Using data from Table I and transport 
measurements performed on 3T3-1 cells during Go, a relationship 
was plotted between nuclear transport  and nuclear receptor oc- 
cupancy. Point A is the tramnuclear  transport rate at Go, while 
points B-D are obtained from data taken from Table I. 
the appearance of EGF binding activity at the cell nucleus. 
Reconstitution studies in cells not expressing EGF receptor 
demonstrated that functional EGF receptors, as functionally 
defined by  ~25I-EGF binding,  originally introduced at  the 
plasma membrane,  can migrate to the nucleus and affect 
transnuclear transport. That the incorporated receptor frac- 
tion, in fact, induces changes in nuclear transport is sup- 
ported by our observation that direct addition of  the receptor 
fraction to isolated NR-6 nuclei enhances nuclear transport. 
~25I-EGF binding studies in whole cells in the presence of 
chloroquine and leupoptin further showed that the observed 
nuclear accumulation of EGF would appear to be a conse- 
quence of  a transport process characteristic of  an endosomal- 
mediated translocation from the plasma membrane to the 
nucleus. These results are consistent with our previous ob- 
servations of an activational role for EGF receptor at the nu- 
cleus (16, 32) and are compatible with reports from other 
laboratories that polypeptide growth factors and polypeptide 
growth factor receptors can be found to accumulate at the nu- 
cleus in whole cells (17, 25, 28, 33, 37, 46, 47). Of additional 
relevance to our proposal for a receptor translocation activa- 
tion mechanism are the observations presented in this com- 
munication and others demonstrating that (a) nuclei isolated 
from growth factor sensitive cells are capable of polypeptide 
growth factor-mediated changes in nuclear function (2, 27, 
32, 36); (b) cells reconstituted with a rat liver EGF receptor 
fraction,  in  which  photoreactive  t25I-EGF  was  shown  to 
covalently bind EGF receptor, result in responsive isolated 
nuclei; and (c) isolated nonresponsive nuclei may be directly 
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demonstrate EGF-mediated enhanced nuclear transport.  An 
alternative to such a direct nuclear activation mechanism that 
has been proposed depends on nonnuclear localized recep- 
tor-dependent changes in a combination of cellular param- 
eters:  i.e.,  phosphatidylinositol  turnover  (44),  free  Ca  ++ 
fluxes (5), or alkalinization of cytoplasmic pH (29). A recent 
publication by Escobedo and Williams (9) provides evidence 
that such types of indirect nuclear signaling may not be suffi- 
cient for the mitogenic response. Through the use of a variety 
of mutant PDGF receptors, they showed that the stimulation 
of phosphatidylinositol  turnover,  cytoplasmic pH alkalini- 
zation,  and  transient  intracellular  calcium  concentration 
changes are not sufficient to explain PDGF-induced mitogen- 
esis. If we view transnuclear transport changes as an element 
of the mitogenic response, the results of Escobedo and Wil- 
liams (9) would appear to suggest that indirect activation may 
be necessary but not sufficient for nuclear activation. 
In viewing our quantitation  of nuclear EGF receptor ac- 
cumulation and those for other polypeptide growth factors 
from other laboratories (12, 25, 33, 37), it is clear that nu- 
clear occupancy reflects a small population of total cell ac- 
cumulation (<5%). Although all such recent investigations 
have gone to great extents to rule out nonfunctional and ar- 
tifactual  whole cell contamination, a point of view has per- 
sisted from earlier work that the nuclear occupancy values 
for polypeptide growth factors are sufficiently low to justify 
an interpretation  in terms of contamination. Yet, the number 
of receptors  found  to  localize  to  the  nucleus  are  within 
amounts required to provide between 0.5 and 1 receptor per 
nuclear pore complex (,~1,000 and 2,000 nuclear pore com- 
plexes are observed in fibroblast and hepatocyte nuclei, re- 
spectively [21]). The growth factor-stimulated receptor (pre- 
viously termed receptorzyme [34]), in conjunction with growth 
factor and/or other associated protein(s) (21,  23, 42),  may 
localize to the nucleus through a receptor-encoded sequence. 
The recent reports of a translocation of activated protein ki- 
nase C  from the plasma membrane to the nucleus may be 
representative  of such a translocation complex possibly con- 
taining  a growth factor receptor (10).  At the nuclear level, 
the activated receptorzyme complex could directly initiate a 
series of enzymatic modifications, leading to changes in nu- 
clear activity as a consequence of modifications in the con- 
formation of nuclear pore complex proteins, nuclear enve- 
lope/matrix structure,  and chromatin organiTation. 
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